Quadrature Capital’s UroGen Pharma URGN Stock Holding History

Quadrature Capital’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,714	Closed	-$354K	–	1674
2025 Q3	$354K	Buy	+17,714	New	+$318K	﹤0.01%	627

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Quadrature Capital's URGN Position: Q4 2025 in Review

Quadrature Capital sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 17,714 shares — an estimated $354K sold.

Quadrature Capital first reported a position in URGN in Q3 2025 and held it in 1 quarter. The position peaked at $354K in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

Quadrature Capital reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
Quadrature Capital sold 17,714 UroGen Pharma shares in Q4 2025, an estimated $354K.
Quadrature Capital first reported a position in UroGen Pharma in Q3 2025 and held it in 1 quarter.
Quadrature Capital's UroGen Pharma position peaked at $354K in Q3 2025.
167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.